Project Grant R21CA274598
Award Date
9/19/23
Completion Date
8/31/25
Dollars Obligated
$401K
Federal Agency
National Cancer Institute
Awardee
Sri International (SRG2J1WS9X63)
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
West Menlo Park, CA 94025, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, is providing $1,504,098.00 to the Sloan-Kettering Institute for Cancer Research to conduct research on the genetic determinants of radiation-associated contralateral breast cancer (CBC). The 5-year project, commencing on May 6, 2025 and concluding on April 30, 2030, aims to identify genetic variants that confer risk for radiation-associated CBC and...
The National Cancer Institute (NCI) awarded a $455,111 Project Grant under CFDA 93.393 "Cancer Cause and Prevention Research" to the Sloan-Kettering Institute for Cancer Research in New York. The 2-year grant, awarded on September 5, 2023, will support research to "Leverage the Hidden Genome to Recover the Missing Heritability of Cancer." The project aims to 1) estimate additional heritability that can be explained by the "hidden genome" (regions of unknown...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $689,934 to the Dana-Farber Cancer Institute (DFCI) to conduct research on the genetic factors underlying immune-related adverse events (IRAEs) associated with immune checkpoint inhibitor (ICI) cancer treatments. The key objectives are to: 1) Perform the largest genome-wide association study (GWAS) of IRAEs across over 13,000 ICI-treated patients, to identify shared and...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $667,485 to the University of California, San Diego to conduct a longitudinal study investigating the mechanisms underlying radiation-induced neurocognitive decline in patients with glioma. The study aims to: 1) Characterize neurocognitive heterogeneity and identify cognitive phenotypes in glioma patients before and after radiation therapy (RT); 2) Analyze biomarkers of...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides funding of $1,104,864 to the University of California, Davis to conduct research on the molecular mechanisms of homologous recombination and chromosome maintenance. The research aims to understand how defects in the proteins involved in DNA pairing, including BRCA2 and the RAD51 paralogs, lead to chromosomal instability and cancer predisposition. The research will use biochemical...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $1,935,588 to the University of Washington to conduct research on genomic analysis of inherited breast and ovarian cancer. The key objectives are to: Identify the spectrum of rare non-coding variants in the regulatory regions of known breast cancer genes using long-read genomic sequencing. Characterize the transcriptional consequences of complex structural variants and rare...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $237,724.00 to Weill Medical College of Cornell University to conduct research on precision use of radiation therapy to induce an in situ cancer immune response. The research aims to determine how the p53 mutation status of a tumor affects the ability of radiation therapy to activate the interferon-I pathway and stimulate an anti-tumor immune response. The project will use mouse...
The National Cancer Institute (NCI) awarded a $581,381 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research in New York. The grant, spanning June 2025 to May 2030, supports research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The research aims to better understand DNA damage repair pathways and how they contribute to genomic instability and...
The National Cancer Institute (NCI) awarded a 5-year, $487,393 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Sloan-Kettering Institute for Cancer Research. The grant will fund research to determine the role of key proteins, including RAD52, HELQ, and POLQ, in backup DNA double-strand break repair pathways in homologous recombination-deficient (HRD) cancers. The research aims to identify additional proteins involved in these alternative repair...